Perceptive Advisors logo

Perceptive Advisors

North America, New York, United States, New York

Description

Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.

Investor Profile

Perceptive Advisors has made 286 investments, with 29 in the past 12 months and 33% as lead.

Stage Focus

  • Post Ipo Equity (26%)
  • Series B (21%)
  • Series C (15%)
  • Series A (10%)
  • Series D (6%)
  • Series Unknown (6%)
  • Post Ipo Debt (5%)
  • Debt Financing (5%)
  • Series E (2%)
  • Private Equity (2%)

Country Focus

  • United States (85%)
  • United Kingdom (4%)
  • Canada (3%)
  • Israel (1%)
  • France (1%)
  • China (1%)
  • Germany (1%)
  • India (1%)
  • Belgium (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Life Science
  • Medical Device
  • Biopharma
  • Health Diagnostics
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Perceptive Advisors frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 28
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 30
CA
North America, Massachusetts, United States, Boston
Co-Investments: 29
Casdin Capital
North America, New York, United States, New York
Co-Investments: 26
RTW Investments
North America, New York, United States, New York
Co-Investments: 32
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 26
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 56
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 24
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 28
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 24

Which angels does Perceptive Advisors often collaborate with?

RS
North America, California, United States, San Francisco
Shared Deals: 1
PM
North America, California, United States
Shared Deals: 2
ME
Europe, England, United Kingdom
Shared Deals: 1
AU
Europe, Hallands Lan, Sweden, Kungsbacka
Shared Deals: 1
Mark W. Hahn
North America, North Carolina, United States, Chapel Hill
Shared Deals: 1
AB
North America, California, United States, Los Angeles
Shared Deals: 2
VS
North America, Massachusetts, United States, Boston
Shared Deals: 1
Daphne Teo
Asia, Singapore
Shared Deals: 1
David Zaccardelli
North America, United States
Shared Deals: 1
DE
Europe, Zurich, Switzerland, Zürich
Shared Deals: 1

What are some of recent deals done by Perceptive Advisors?

Exagen

Vista, California, United States

Exagen is a patient focused, discovery-driven life science company serving patients affected by autoimmune rheumatic diseases.

BiotechnologyGeneticsHealth CareHealth DiagnosticsLife ScienceMedicalTherapeutics
Post Ipo DebtApr 28, 2025
Amount Raised: $25,000,000
Merida Biosciences

Cambridge, Massachusetts, United States

Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.

BiotechnologyLife ScienceTherapeutics
Series AApr 8, 2025
Amount Raised: $121,000,000
Caris Life Sciences

Irving, Texas, United States

Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.

Artificial Intelligence (AI)BiopharmaBiotechnologyHealth CareLife Science
Private EquityApr 7, 2025
Amount Raised: $168,000,000
Edgewise Therapeutics

Boulder, Colorado, United States

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityApr 2, 2025
Amount Raised: $200,000,000
Opus Genetics(formerly Ocuphire Pharma)

Farmington Hills, Michigan, United States

Ocuphire Pharma, a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

BiopharmaBiotechnologyPharmaceutical
Post Ipo EquityMar 21, 2025
Amount Raised: $20,000,000
Solid Biosciences

Marlborough, Massachusetts, United States

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquityFeb 18, 2025
Amount Raised: $200,000,000
Kardigan

South San Francisco, California, United States

Kardigan is a patient-driven heart health firm that is revolutionizing cardiovascular drug development to produce medicines.

BiopharmaHealth CareMedical
Series AJan 10, 2025
Amount Raised: $300,000,000
Outset Medical

San Jose, California, United States

Outset Medical is a medical technology company that offers reimagining dialysis for patients and providers.

Health CareHealth DiagnosticsMedicalMedical Device
Post Ipo DebtJan 6, 2025
Amount Raised: $125,000,000
Rapt Therapeutics

South San Francisco, California, United States

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Post Ipo EquityDec 23, 2024
Amount Raised: $150,000,000
Beta Bionics

Irvine, California, United States

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

BiotechnologyDiabetesMedical Device
Series ENov 13, 2024
Amount Raised: $60,000,000